{'fraction_non_alphanumeric': 0.06800445930880714, 'fraction_numerical': 0.045707915273132664, 'mean_word_length': 4.8311688311688314, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)].

The analysis is presented of combined treatment of locally advanced prostatic cancer (LAPC), stage T3NXM0, in 158 LAPC patients treated in 1998-2002. The patients were divided into four groups: group 1 (n=72) received hormones in parallel with radiation, group 2 (n=52) received only hormones, group 3 (n=27) received radiotherapy after failure of long-term (1 year and more) hormone therapy, group 4 (n=7) was given teleradiotherapy only. 3-year recurrence-free survival in patients with LAPC showed advantage of the combined treatment (82 +/- 0.1%) vs hormone (56 +/- 0.1%) or radiation (69.3 +/- 0.1%) therapy alone. It provides a high local control over the primary tumor and an increase of survival, prolongs distant metastases free period, improves the patients' quality of life and their adaptation.